A innovative method in the lung cancer therapy, particularly in EGFR mutation carriers, is the osimertinib treatment regimen.By offering a more tailored and effective therapy option, this precision medicine has transformed the oncology field.medical practitioners can enhance patient care and increase efficacy by comprehending the complexities of the osimertinib treatment regimen.A third-generation EGFR TKI (TKI), osimertinib, specifically targets the EGFR signaling pathway.By inhibiting the function of the EGFR protein, which is often abnormally expressed in lung cancer cells, it works.This inhibition prevents the EGFR from encouraging cell proliferation, proliferation, differentiation,…
